Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004)

Clinical and Experimental Rheumatology

Volumn 24, Issue 1, 2006, Pages 65-69

  Scheinberg, Morton ^a,e   Hamerschlak, Nelson ^a   Ribeiro, Andreza A F ^a   Ferreira, Euripedes ^a   Goldenberg, José ^a,b   Kiss, Maria H ^c   Chahade, William H ^d  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Hospital do Servidor do Estado de São Paulo   (Brazil)

^e NONE   (Brazil)

Author keywords

Arthritis; Autoimmune diseases; B lymphocytes; Lupus erythematosus; Rituximab; Thrombocytopenic purpura

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BRAZIL; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERANCE; EOSINOPHILIC FASCIITIS; FEMALE; FEVER; HUMAN; HYPERGAMMAGLOBULINEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SCORING SYSTEM; SHORT COURSE THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ADOLESCENT; ADULT; AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BRAZIL; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33645068869     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. TSUBATA T, HONJO T: B cell tolerance and autoimmunity. Rev Immunogenetic 2000; 2: 18-25.
2. PARAKISHVILI N: Recent progress in the understanding of B cell functions in autoimmunity. Scand J Immunol 2001; 54: 30-8.
3. MOORE PA: Blys: member of the tumor necrosis factor family and B lymphocyte stimulation. Science 1999; 285: 260-3.
4. MELCHERS F: Action of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 2003; 62: 25-7.
5. REFF ME, CEVNERK, CHAMBERS KS et al.: Refletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 15: 435-45.
6. LAMB HM, BARNAM BALFOUR SA: Rituximab. Drugs 1995; 58: 79-88.
7. PREVOO ML, van HOFF MA, KUPER HH, van LEUWAN MA, van de PUTTE LB, Van RIEL PL: Modified disease activity scores that include twenty eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
8. URIBE AG, VILA CM, McGWIN Jr, SANCHEZ ML, REVEILLE JD, ALARCON GS: The Systemic Lupus Activity Measure revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and a modified SLEDAI-2K are adequate instruments to measure disease activity in SLE. J Rheumatol 2004; 31: 1934-40.
9. EDWARDS JC, SZCZEPANSKI L, SZECHINSKI I et al.: Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
10. LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-7.
11. LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-9.
12. ARMSTRONG DJ, WRIGHT SA, FUNCH MB, TAGGART AJ, BELL AL: Active systemic lupus erythematosus successfully treated with Rituximab and oral steroid. Clin Exp Rheumatol 2004: 22: 787-8.
13. RAMANATHAN S, KOUTTS J, HERTZBERG MS: Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Haematol 2005; 78: 123-6.
14. SCHEINBERG M, HAMERSCHLAK N, KUTNER SM, RIBEIRO AFR: Rituximab: uma alternativa terapêutica para o tratamento da trombocitopenia imunológica. Res Brasil Reumatol 1995; 43: 79-88.
15. SHANAFELDT TD, MADNEMETH HL, WOLF RC, TEFFERI A: Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Evans syndrome. Mayo Clinic Proc 2003; 78: 1340-6.
16. MALAVIYA NA, KAUSHIK P, BUDHIRAJA S et al.: Hypergammaglobulinemic purpura of Waldenstrom: report of cases with a short review. Clin Exp Rheumatol 2000; 18: 518-22.
17. DOYLE JA, GINSBURG WW: Eosinophilic fasciitis. Med Clin North Am 1989; 73: 1157-66.
18. GOTTENBERG J, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 913-20, 2005
19. SCHEINBERG MA: Depleção de células B, uma nova alternativa em doenqas autoimunes. Einstein 2005; 2: 39-42.
20. CHAMBERS AS, ISENBERG D: Anti B cell therapy (Rituximab) in the treatment of autoimmune diseases. 2005; 14: 210-4.
21. LOONEY RJ: B cells as a therapeutic target in autoimmunediseases other than rheumatoid arthritis. Rheumatology 2005; 44: 13-7.